Daniel Day

Daniel R. Day advises clients on a combination of evidence collection strategy, clinical evidence translation, and market insight related to medical products.

Specifically, Dr. Day focuses on aspects of quality measurement as they relate to the translation of clinical guidelines for use in pay-for-reporting and pay-for-performance programs. In this role he assists clients in shaping tactical plans and in the execution of quality measure assessment, feasibility, and development.

Prior to joining Avalere, he served as a member of the Scientific Advisory Board and program coordinator with Terosin Group, Inc., and as a visiting scientist at the University of California at Santa Barbara.

Daniel has a PhD in pharmacology, an MA in molecular cellular biology, and a BS in biological sciences from the University of California at Santa Barbara.

Authored Content

Avalere’s white paper draws on recommendations from a multi-stakeholder workshop to look at roadblocks and solutions for scaling sustainable solutions to address the diagnosis of rare disease.

This past spring, Avalere and MITRE experts presented “Implementation of the Core Quality Measures Collaborative (CQMC) Core Measure Sets by Public Payers: Successes and Opportunities” at the Pharmacy Quality Alliance (PQA) annual meeting.

Cancer is a burden to patients and the healthcare system. Last year, an estimated 1.6 million new cancer cases were diagnosed in the U.S and the latest figures estimate that 13.4 million people, about 4 percent of the U.S. population, live with cancer in the U.S.1